AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7870986 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 128
Study 2430606 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1
Number of subjects: 20
Study 2430606 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.12 mg kg‐1
Number of subjects: 20
Study 30071333 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐C2 fusion
Number of subjects: 165
Study 30071333 — intervention group
Group type: COMPARATOR
Intervention: Occipito-Cervical (O-C) fusion
Number of subjects: 165
Study 30071333 — intervention group
Group type: COMPARATOR
Intervention: O-C fusion
Number of subjects: 165
Study 27020669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet plus potassium supplement for 7 days
Number of subjects: 49
Study 27020669 — intervention group
Group type: COMPARATOR
Intervention: High-salt diet
Number of subjects: 49
Study 27020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Jurkat cells treated with 40 mM NaCl
Number of subjects: 49
Study 27020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Jurkat cells treated with additional 2 mM KCl
Number of subjects: 49
Study 24998242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive working memory training (computer-based program, 25 daily sessions over 5 to 6 weeks)
Number of subjects: 115
Study 24998242 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 115
Study 21835953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (ASA) 100 mg/d (n = 176)
Number of subjects: 342
Study 21835953 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) enoxaparin 40 mg/d (n = 166)
Number of subjects: 342
Study 21835953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASA and LMWH
Number of subjects: 342
Study 19832854 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) - human recombinant PTH 1-34, 20 microg daily injections for 18 months
Number of subjects: 31
Study 19832854 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (16 age- and gender-matched)
Number of subjects: 31
Study 18698292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone
Number of subjects: 693
Study 18698292 — intervention group
Group type: COMPARATOR
Intervention: Focal/grid photocoagulation
Number of subjects: 693
Study 18698292 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 693
Study 15952104 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alfa 2b 1.5 microg/kg/wk
Number of subjects: 61
Study 15952104 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alfa 2b 3.0 microg/kg/wk
Number of subjects: 61
Study 15952104 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alfa 2b 1.5 or 3.0 microg/kg/wk (split-dose)
Number of subjects: 61
Study 15952104 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alfa 2b 3 mIU 3 times weekly
Number of subjects: 61
Study 12072849 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG signal of the paraspinal musculature at L3 during quiet stance using different normalization techniques
Number of subjects: 0
Study 12072849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral asymmetry of paraspinal musculature in segments exhibiting pain
Number of subjects: 0
Study 12072849 — intervention group
Group type: COMPARATOR
Intervention: Dynamic asymmetry of paraspinal musculature during forward bending
Number of subjects: 0
Study 10332129 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 percent lidocaine with 1:100,000 epinephrine
Number of subjects: 42
Study 10332129 — intervention group
Group type: COMPARATOR
Intervention: 3 percent mepivacaine
Number of subjects: 42
Study 8739019 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1452 (10 mg, 25 mg, 50 mg)
Number of subjects: 8
Study 8739019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1763923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine LA 50 mg administered twice daily
Number of subjects: 38
Study 1763923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6980756 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic tumor vaccine
Number of subjects: 40
Study 6980756 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving tumor vaccine)
Number of subjects: 40
Study 30334124 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photobiomodulation therapy (lPBMt) with an exercise program for 8 weeks
Number of subjects: 45
Study 30334124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (UST) with an exercise program for 8 weeks
Number of subjects: 45
Study 30334124 — intervention group
Group type: COMPARATOR
Intervention: Control group with only the exercise program for 8 weeks
Number of subjects: 45
Study 28129246 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 117
Study 28129246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 25956261 — intervention group
Group type: EXPERIMENTAL
Intervention: 37 °C group
Number of subjects: 1338
Study 25956261 — intervention group
Group type: COMPARATOR
Intervention: RT group
Number of subjects: 1338
Study 24360649 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (both depressed and non-depressed)
Number of subjects: 80
Study 24360649 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed non-smokers
Number of subjects: 80
Study 24360649 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers who are not depressed
Number of subjects: 80
Study 24360649 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed non-smokers and both groups of smokers
Number of subjects: 80
Study 22646848 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth cardiac rehabilitation exercise intervention
Number of subjects: 20
Study 19491386 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid, 500 mg every day)
Number of subjects: 8171
Study 19491386 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (RRR‐alpha‐tocopherol acetate, 600 IU every other day)
Number of subjects: 8171
Study 19491386 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg every other day)
Number of subjects: 8171
Study 19491386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8171
Study 16937979 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g.d(‐1) of whey protein + 8 g.d(‐1) of casein (WC)
Number of subjects: 36
Study 16937979 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g.d(‐1) of whey protein + 3 g.d(‐1) branched-chain amino acids + 5 g.d(‐1) L-glutamine (WBG)
Number of subjects: 36
Study 16937979 — intervention group
Group type: COMPARATOR
Intervention: 48 g per day (g.d(‐1)) carbohydrate placebo (P)
Number of subjects: 36
Study 14962152 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg and rifampin 300 mg daily for 3 months
Number of subjects: 101
Study 14962152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 11738746 — intervention group
Group type: EXPERIMENTAL
Intervention: 23‐valent pneumococcal polysaccharide vaccine (PSV)
Number of subjects: 60
Study 11738746 — intervention group
Group type: COMPARATOR
Intervention: Control group (conjugate Haemophilus influenzae type b (HbOC) vaccine)
Number of subjects: 60
Study 9158644 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (100 or 200 mg BID)
Number of subjects: 916
Study 9158644 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (to obtain an international normalized ratio of 2.0 to 3.5)
Number of subjects: 916
Study 9158644 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (control group)
Number of subjects: 916
Study 7714411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac Na
Number of subjects: 165
Study 7714411 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Na
Number of subjects: 165
Study 3067479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifyllin 1200 mg daily for 3 months
Number of subjects: 90
Study 3067479 — intervention group
Group type: COMPARATOR
Intervention: Control group (39 infertile men)
Number of subjects: 90
Study 30186817 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-T-lymphocyte globulin (ATG)
Number of subjects: 40
Study 30186817 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (BAS)
Number of subjects: 40
Study 28954926 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-520 (RNA interference-based therapeutic targeting HBV transcripts)
Number of subjects: 0
Study 26154657 — intervention group
Group type: EXPERIMENTAL
Intervention: Native banana starch (NBS)
Number of subjects: 0
Study 26154657 — intervention group
Group type: COMPARATOR
Intervention: Digestible corn starch (DCS)
Number of subjects: 0
Study 23763082 — intervention group
Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1% for 2 weeks
Number of subjects: 147
Study 23763082 — intervention group
Group type: COMPARATOR
Intervention: Vehicle for 2 weeks
Number of subjects: 147
Study 23763082 — intervention group
Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1% for 4 weeks
Number of subjects: 147
Study 23763082 — intervention group
Group type: COMPARATOR
Intervention: Vehicle for 4 weeks
Number of subjects: 147
Study 21398574 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-L total disc replacement
Number of subjects: 237
Study 21398574 — intervention group
Group type: COMPARATOR
Intervention: Circumferential arthrodesis
Number of subjects: 237
Study 18297353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard colonoscope with transparent hood
Number of subjects: 372
Study 18297353 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope without transparent hood
Number of subjects: 372
Study 18297353 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-caliber colonoscope with transparent hood
Number of subjects: 372
Study 18297353 — intervention group
Group type: COMPARATOR
Intervention: Small-caliber colonoscope without transparent hood
Number of subjects: 372
Study 16091238 — intervention group
Group type: EXPERIMENTAL
Intervention: STI interventions
Number of subjects: 0
Study 16091238 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based randomized controlled trials
Number of subjects: 0
Study 16091238 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective treatment of curable STIs
Number of subjects: 0
Study 16091238 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical services related to STI interventions
Number of subjects: 0
Study 11601117 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg, once daily)
Number of subjects: 1513
Study 11601117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 9606227 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate bolus strategy (3 mL intratracheal bolus of calf lung surfactant extract - Infasurf administered before positive pressure ventilation)
Number of subjects: 651
Study 9606227 — intervention group
Group type: EXPERIMENTAL
Intervention: Postventilatory aliquot strategy (3 mL of surfactant administered in 4 divided aliquots of 0.75 mL each at 10 minutes after birth)
Number of subjects: 651
Study 9606227 — intervention group
Group type: COMPARATOR
Intervention: Immediate bolus strategy
Number of subjects: 651
Study 9606227 — intervention group
Group type: EXPERIMENTAL
Intervention: Postventilatory aliquot strategy
Number of subjects: 651
Study 7740450 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 150 U/kg s.c.
Number of subjects: 18
Study 7740450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose LMWH 35 U/kg s.c.
Number of subjects: 18
Study 7740450 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose LMWH 75 U/kg s.c.
Number of subjects: 18
Study 7740450 — intervention group
Group type: COMPARATOR
Intervention: UFH and LMWH
Number of subjects: 18
Study 2557322 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g NaHCO3/kg body wt)
Number of subjects: 6
Study 2557322 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.12 g NaHCO3/kg body wt initially, with 0.18 g/kg body wt distributed in equal doses before each 5‐min exercise bout)
Number of subjects: 6
Study 2557322 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (placebo control)
Number of subjects: 6
Study 1222886 — intervention group
Group type: EXPERIMENTAL
Intervention: C-3 (2 g statim plus 6 g by continuous drip infusion over 24 hrs for 5 days)
Number of subjects: 391
Study 1222886 — intervention group
Group type: EXPERIMENTAL
Intervention: C-3
Number of subjects: 391
Study 1222886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 1222886 — intervention group
Group type: EXPERIMENTAL
Intervention: C-3 (for more than 24 hours)
Number of subjects: 391
Study 1222886 — intervention group
Group type: EXPERIMENTAL
Intervention: C-3 (for more than 12 hours, male patients)
Number of subjects: 391
Study 1222886 — intervention group
Group type: EXPERIMENTAL
Intervention: C-3 (for patients less than 60 years old)
Number of subjects: 391
Study 1222886 — intervention group
Group type: EXPERIMENTAL
Intervention: C-3 (for patients less than 60 years old, for more than 12 hours)
Number of subjects: 391
Study 30389750 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 449
Study 30389750 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 449
Study 30389750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 28485320 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized Amikacin (400 mg, q8h) for 7 days
Number of subjects: 52
Study 28485320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 4 ml, q8h) for 7 days
Number of subjects: 52
Study 25659550 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional herniotomy (Group A)
Number of subjects: 784
Study 25659550 — intervention group
Group type: COMPARATOR
Intervention: Mini-invasive herniotomy (Group B)
Number of subjects: 784
Study 23714133 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic femoroacetabular impingement
Number of subjects: 30
Study 23714133 — intervention group
Group type: COMPARATOR
Intervention: Healthy, pain-free control group
Number of subjects: 30
Study 22118109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftiofur hydrochloride intramammary infusion at 24-hour intervals for 5 days
Number of subjects: 104
Study 22118109 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 104
Study 22118109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftiofur hydrochloride intramammary infusion
Number of subjects: 104
Study 19201570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography with low ejection fraction
Number of subjects: 3259
Study 19201570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography with extent of ischemia
Number of subjects: 3259
Study 19201570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fractions < 30%
Number of subjects: 3259
Study 17110799 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 or 50 mg)
Number of subjects: 15
Study 17110799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15222407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 325
Study 15222407 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg)
Number of subjects: 325
Study 15222407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 325
Study 15222407 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 325
Study 11250189 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed postoperative drainage fluid (Group A)
Number of subjects: 166
Study 11250189 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood processed from the cardiopulmonary bypass (CPB) circuit (Group B)
Number of subjects: 166
Study 11250189 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 166
Study 9218208 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril and verapamil
Number of subjects: 100
Study 9218208 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril alone
Number of subjects: 100
Study 8317790 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase) 0.6 mg twice daily
Number of subjects: 181
Study 8317790 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase) 2.5 mg twice daily
Number of subjects: 181
Study 8317790 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase) 10.0 mg twice daily
Number of subjects: 181
Study 8317790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 2952213 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐Trp‐6‐LHRH
Number of subjects: 104
Study 2952213 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 104
Study 29608427 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 second interval
Number of subjects: 40
Study 29608427 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 second interval
Number of subjects: 40
Study 29608427 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 second interval
Number of subjects: 40
Study 26253453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (IPO)
Number of subjects: 30
Study 26253453 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 23897769 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab+MTX
Number of subjects: 461
Study 22739373 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon consumption (2 portions of farmed salmon per week providing 3.45 g long‐chain (LC) (n‐3) PUFA/wk)
Number of subjects: 123
Study 22739373 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon consumption
Number of subjects: 123
Study 22739373 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 123
Study 22739373 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 20497950 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% ethanol beer
Number of subjects: 12
Study 20497950 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free beer
Number of subjects: 12
Study 18318696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsi Cola added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75
Study 18318696 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium citrate added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75
Study 18318696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75
Study 18318696 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice added to 0.75 mg x kg(‐1) midazolam
Number of subjects: 75
Study 18318696 — intervention group
Group type: COMPARATOR
Intervention: 0.75 mg x kg(‐1) midazolam without any additive
Number of subjects: 75
Study 16046950 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist blood pressure oscillometer
Number of subjects: 2493
Study 16046950 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 2493
Study 12217670 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy
Number of subjects: 27
Study 12217670 — intervention group
Group type: COMPARATOR
Intervention: Conventional discectomy
Number of subjects: 27
Study 9527730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation (5 mg kg(‐1) h(‐1) initially, titrated to 2.4+/‐0.7 mg kg(‐1) h(‐1))
Number of subjects: 10
Study 9527730 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 10
Study 9527730 — intervention group
Group type: COMPARATOR
Intervention: Control (i.v. saline)
Number of subjects: 10
Study 9527730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 10
Study 7629525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (30 or 283 mg)
Number of subjects: 2437
Study 2799022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride (7.5 mg/kg)
Number of subjects: 16
Study 2799022 — intervention group
Group type: COMPARATOR
Intervention: Dihydrobenzoperidol plus fentanyl
Number of subjects: 16
Study 2799022 — intervention group
Group type: COMPARATOR
Intervention: Diazepam plus haloperidol
Number of subjects: 16
Study 62946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus isoniazid for nine months, supplemented by ethambutol (25 mg/kg for the first two months)
Number of subjects: 696
Study 62946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus isoniazid for twelve months, supplemented by ethambutol
Number of subjects: 696
Study 62946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus isoniazid for six months, supplemented by ethambutol
Number of subjects: 696
Study 62946 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin (adverse effects noted)
Number of subjects: 696
Study 30796855 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous lactase preparation
Number of subjects: 40
Study 30796855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose diet
Number of subjects: 40
Study 30796855 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 40
Study 28489856 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue ART
Number of subjects: 1652
Study 28489856 — intervention group
Group type: COMPARATOR
Intervention: Discontinue ART
Number of subjects: 1652
Study 25582225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression network methods
Number of subjects: 0
Study 25582225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 0
Study 25582225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene set enrichment analysis
Number of subjects: 0
Study 25582225 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biomarker myeloperoxidase (MPO)
Number of subjects: 0
Study 22246615 — intervention group
Group type: COMPARATOR
Intervention: Informational booklet
Number of subjects: 99
Study 22246615 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet + face‐to‐face parent training sessions
Number of subjects: 99